NorthStar Medical Radioisotopes Partners with University of Wisconsin to Accelerate Radiopharmaceutical Development
核心洞察
NorthStar Medical Radioisotopes (搜索) has formed a multi-year strategic partnership with the University of Wisconsin School of Medicine and Public Health (搜索) to advance radiopharmaceutical research and development.
The collaboration will focus on joint clinical and translational research, comprehensive drug development services, and workforce development in nuclear medicine.
The partnership aims to accelerate new radiopharmaceutical therapies to market by leveraging the university's research infrastructure and NorthStar's commercial-scale radioisotope production capabilities.
NorthStar Medical Radioisotopes (搜索), a leading commercial-stage radiopharmaceutical company, has announced a comprehensive strategic partnership with the University of Wisconsin School of Medicine and Public Health (搜索) to advance research and development in the rapidly growing nuclear medicine sector. The multi-year collaboration will work closely with the university's Initiative for Theranostics and Particle Therapy (ITPT) to foster innovation and strengthen nuclear medicine development in Wisconsin.
The partnership represents a significant step toward creating closer ties between industry and academia, with the goal of accelerating new radiopharmaceutical therapies from concept to commercialization. According to Dr. Frank Scholz, CEO at NorthStar, "We're thrilled to partner with one of the nation's leading academic institutions to drive sector innovation and help accelerate new therapies to market. This partnership underscores our commitment to staying at the forefront of the industry and developing the talent pool that will be required to support the significant growth expected in our industry."
Comprehensive Drug Development Services
The collaboration will leverage the university's advanced research infrastructure, scientific expertise, and capabilities to expand the preclinical and early-stage development services that NorthStar offers. This integrated approach aims to provide a one-stop expert resource supporting all stages of drug development from initial concept through commercialization.
The partnership will focus on three key areas: collaborative research, clinical and translational research, and contract research and drug development. Joint research collaborations will support clinical and translational drug discovery through the combined efforts of scientists and radiochemists from both NorthStar and ITPT.
Workforce Development Initiative
A critical component of the partnership involves education and workforce development in the nuclear medicine field. The collaboration will provide structured training opportunities at NorthStar, giving students practical, career-building experiences while helping NorthStar and other Wisconsin nuclear medicine firms develop talent for the next generation of professionals.
"The new collaboration with NorthStar will build on University of Wisconsin School of Medicine and Public Health (搜索)'s strong leadership in radiopharmaceutical and theranostics R&D, yielding highly productive, impactful research and educational opportunities," said Nita Ahuja, MD, MBA, Dean of the school and Vice Chancellor for Medical Affairs at the University of Wisconsin–Madison. "This partnership aligns with our mission to advance health with innovative research that extends beyond the university, in alignment with the Wisconsin Idea."
NorthStar's Radiopharmaceutical Capabilities
NorthStar Medical Radioisotopes (搜索) specializes in utilizing novel technologies to produce commercial-scale radioisotopes that, once attached to molecules, can detect and treat cancer (搜索) and other serious diseases. The company's expanding industry-leading position in radiopharmaceutical therapy is supported by its unique capabilities in sophisticated radioisotope production, proven management team, and state-of-the-art, environmentally preferable technologies.
The company produces copper-67 (搜索) (Cu-67) and is positioned to become one of the first commercial-scale producers of non-carrier added actinium-225 (搜索) (n.c.a. Ac-225). NorthStar's Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs.
Academic Excellence in Nuclear Medicine
The University of Wisconsin School of Medicine and Public Health (搜索), founded in 1907 and recognized as one of the nation's leading institutions in health sciences education, research, and service, became the first school to integrate medicine and public health disciplines in 2005. The school employs more than 5,600 faculty and staff and provides educational opportunities for nearly 3,000 students and postgraduate trainees.
For federal fiscal year 2024, the school ranked ninth in the nation among public medical schools for NIH funding according to the Blue Ridge Institute for Medical Research. The faculty includes several National Medal of Science recipients and National Academy of Science honorees.
The partnership officially launches in September 2025, with several initiatives already underway. This collaboration is expected to strengthen regional innovation and expertise in nuclear medicine while creating academic and real-world educational opportunities to develop a skilled radiopharmaceutical talent pool.